Ibandronate- Second generation biophosphonate drug and its therapeutic uses

DESCRIPTION
 It belongs to a group of medicines called bisphosphonates . It alters the cycle of bone formation and   breakdown in the body.
 Ibandronate slows bone loss while increasing bone mass, which may prevent bone fractures.


PHARMACOKINETICS

1. Poorly absorbed

2. Volume of distribution 90L.

3. Protein binding is 90.9 to 99.5% over an ibandronate concentration range of 2 to 10 mg/ml.
4. Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged            in the feces.
5. Half life is 10-60 hours.


THERAPEUTIC USES
It is used to treat or prevent osteoporosis in women after menopause.


SIDE EFFECTS
• Bladder pain
• Bloody or cloudy urine
• Chest pain
• Cough producing mucus
• Difficult, burning, or painful urination
• Difficulty with breathing
• Fever or chills
• Frequent urge to urinate
• Lower back or side pain
• Nervousness
• Pounding in the ears
• Shortness of breath
• Slow or fast heartbeat
• Sneezing
• Sore throat
• Tightness in the chest


DRUG-DRUG INTERACTIONS
1. Ibandronate + Amikacin = Increase the activities of Ibandronate.
2. Ibandronate + Bevacizumab = The risk or severity of adverse effects can be increased.
3. Ibandronate + Citalopram = Increase in the QTc-prolonging activities of Citalopram.
4. Ibandronate + Esomeprazole = The therapeutic efficacy of Ibandronate can be decreased.
5. Ibandronate + Magnesium Sulfate = The serum concentration of Ibandronate can be decreased.

REFERENCE- Tripathi K.D. "Essentials of Medical Pharmacology", 7th Edition, page no- 343
\